2023 Editor's Choice

January 2023

Patient-Reported Satisfaction, Experiences, and Preferences: Same but Different?

Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges

The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data

Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review

February 2023

A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force

Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?

A Scoping Review of the Use of Machine Learning in Health Economics and Outcomes Research: Part 1—Data From Wearable Devices

Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib

Quality-Adjusted Life Expectancy Norms for the English Population

March 2023

Drug Pricing Throughout the Product Lifecycle: A Work in Progress

Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the “Age of Cures” and Their Implications for Dynamic Efficiency

The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies

Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions

Equitable Prioritization of Health Interventions by Incorporating Financial Risk Protection Weights Into Economic Evaluations

April 2023

Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Step Forward

Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force

Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised

Mapping Studies to Estimate Health-State Utilities From Nonpreference-Based Outcome Measures: A Systematic Review on How Repeated Measurements are Taken Into Account

May 2023

Cost-Effectiveness of Medication Therapy Management Program Across Racial and Ethnic Groups Among Medicare Beneficiaries

 Dealing With Uncertainty in Early Health Technology Assessment: An Exploration of Methods for Decision Making Under Deep Uncertainty

 Do Misconceptions About Health-Related Quality of Life Affect General Population Valuations of Health States?

June 2023

Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany

A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021)

Stakeholder Engagement in Designing Attributes for a Discrete Choice Experiment With Policy Implications: An Example of 2 Swiss Studies on Healthcare Delivery

Eliciting Trade-Offs Between Equity and Efficiency: A Methodological Scoping Review

July 2023

Methods to Adjust Willingness-to-Pay Measures for Severity of Illness

Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?

Designing a Value-Based Formulary for a Commercial Health Plan: A Simulated Case Study of Diabetes Medications

Health Technology Assessment–Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England

A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample

August 2023

A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report

The Economic Cost of Thyroid Cancer in France and the Corresponding Share Associated With Treatment of Overdiagnosed Cases

Developing Criteria for Health Economic Quality Evaluation Tool

September 2023

Data Privacy and Health: How Do We Achieve the Right Balance?

A New Type 2 Diabetes Microsimulation Model to Estimate Long-Term Health Outcomes, Costs, and Cost-Effectiveness

Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs

Does EQ-5D Tell the Whole Story? Statistical Methods for Comparing the Thematic Coverage of Clinical and Generic Outcome Measures, With Application to Breast Cancer

Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: A Comprehensive Review of Approaches and Challenges

October 2023

Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration

A Value Framework to Assess Patient-Facing Digital Health Technologies That Aim to Improve Chronic Disease Management: A Delphi Approach

Estimating the US Baseline Distribution of Health Inequalities Across Race, Ethnicity, and Geography for Equity-Informative Cost-Effectiveness Analysis

The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE’s New Methods Manual

Adaptive Health Technology Assessment: A Scoping Review of Methods

November 2023

Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology

On the (Near) Equivalence of Welfarist and Extra-Welfarist Methods to Value Healthcare With Implications for Assessing Equity

Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions

Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations

December 2023

Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community

Has the Centers for Medicare Medicaid Services Implicitly Adopted a Value Framework for Medicare Drug Price Negotiations?

Faster Diagnosis and Treatment for Cancer: Assessing Patient Pathways Using a Panel Regression Analysis of the English National Cancer Registration Data

An Intersectional Approach to Quantifying the Impact of Geographic Remoteness and Health Disparities on Quality-Adjusted Life Expectancy: Application to Australia

Preferences for Palliative and End-of-Life Care: A Systematic Review of Discrete Choice Experiments